



**HAL**  
open science

## Intestinal adaptation in short bowel syndrome. What is new?

Lore Billiauws, Muriel Thomas, Johanne Le Beyec-Le Bihan, Francisca Joly

### ► To cite this version:

Lore Billiauws, Muriel Thomas, Johanne Le Beyec-Le Bihan, Francisca Joly. Intestinal adaptation in short bowel syndrome. What is new?. *Nutrición Hospitalaria*, 2018, 35 (3), pp.731-737. 10.20960/nh.1952 . hal-02621007

**HAL Id: hal-02621007**

**<https://hal.inrae.fr/hal-02621007>**

Submitted on 26 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



## Revisión

### Intestinal adaptation in short bowel syndrome. What is new?

#### *Adaptación intestinal en el síndrome de intestino corto: ¿qué hay de nuevo?*

Lore Billiauws<sup>1,2</sup>, Muriel Thomas<sup>3</sup>, Johanne Le Beyec-Le Bihan<sup>2,4</sup> and Francisca Joly<sup>1,2</sup>

<sup>1</sup>Department of Gastroenterology and Nutrition Support. APHP Beaujon Hospital. Clichy, France. <sup>2</sup>Gastrointestinal and Metabolic Dysfunctions in Nutritional Pathologies. Inserm UMR 1149. Centre de Recherche sur l'Inflammation Paris Montmartre. UFR de Médecine Paris Diderot. Paris, France. <sup>3</sup>Micalis Institute - INRA, AgroParisTech. Université Paris-Saclay. Jouy-en-Josas, France. <sup>4</sup>Department of Endocrine and Oncological Biochemistry. Sorbonne University. UPMC Univ Paris 06, AP-HP. Pitié-Salpêtrière Hospital. Paris, France

### Abstract

#### Key words:

Short bowel syndrome. Intestinal failure. Parenteral nutrition. GLP-2 analog. Intestinal adaptation.

Short bowel syndrome (SBS) is a well-known cause of intestinal failure (IF) (1). SBS occurs after extensive resection of the small bowel (RSB) resulting in a bowel length of less than 150/200 cm. The colon may have been partially or completely removed. SBS patients experience severe water and nutrient malabsorption, so that they are often managed with parenteral nutrition (PN) to supplement their oral intake (2-4). A complete understanding of the pathophysiology of SBS and postoperative adaptations may allow identifying the spontaneous processes that compensate for the reduction in absorptive surface. A better knowledge of these adaptive mechanisms may help to improve the management of patient nutrition, to reduce the need for PN and to prevent D-encephalopathy episodes. This review focuses on the overall adaptations described in adult SBS patients but does not review pediatric cases.

#### Palabras clave:

Síndrome de intestino corto. Fallo intestinal. Nutrición parenteral. Adaptación intestinal. Agonista GLP2.

### Resumen

El síndrome del intestino corto es la primera causa de fallo intestinal (que requiere suplementación intravenosa de fluidos, electrolitos y/o calorías). La adaptación fisiológica intestinal ocurre uno a dos años después de la resección quirúrgica. Esta adaptación incluye hiperfagia, cambios en la microbiota, cambios morfológicos intestinales (incluida la hiperplasia), adaptaciones hormonales y otros. . . El colon desempeña un papel importante y permite la recuperación hidroelectrolítica y energética. Es posible mejorar la adaptación fisiológica mediante la optimización de la intervención dietética, restaurando la continuidad y tratando con factores de crecimiento, como el análogo del GLP-2 (*glucagon-like peptide-2*).

Received: 03/04/2018 • Accepted: 03/04/2018

Billiauws L, Thomas M, Le Beyec-Le Bihan J, Joly F. Intestinal adaptation in short bowel syndrome. What is new? *Nutr Hosp* 2018;35:731-737

DOI: <http://dx.doi.org/10.20960/nh.1952>

#### Correspondence:

Francisca Joly. Department of Gastroenterology and Nutrition Support. APHP Beaujon Hospital. 100 Boulevard du Général Leclerc, 92110 Clichy, France  
e-mail: francisca.joly@gmail.com

## INTRODUCTION

Short bowel syndrome (SBS) is a well-known cause of intestinal failure (IF) (1). SBS occurs after extensive resection of the small bowel (RSB) resulting in a bowel length of less than 150/200 cm. The colon may have been partially or completely removed. SBS patients experience severe water and nutrient malabsorption, so that they are often managed with parenteral nutrition (PN) to supplement their oral intake (2-4). A complete understanding of the pathophysiology of SBS and postoperative adaptations may allow identifying the spontaneous processes that compensate for the reduction in absorptive surface. A better knowledge of these adaptive mechanisms may help to improve the management of patient nutrition, to reduce the need for PN and to prevent D-encephalopathy episodes. This review focuses on the overall adaptations described in adult SBS patients but does not review pediatric cases.

## INTESTINAL FAILURE AND SHORT BOWEL SYNDROME

Intestinal failure (IF) occurs in various gastrointestinal diseases such as gut motility disorders, mechanical obstruction, intestinal fistula, extensive small bowel mucosal disease, volvulus or systemic conditions such as mesenteric infarction and post-radiation enteritis. IF is defined as a reduction in gut function below the minimum needed for the absorption of macronutrients and/or water and electrolytes, resulting in intravenous (IV) supplementation to maintain health and/or growth (1).

Three different types of IF have been described based on duration: a) acute, short-term and usually self-limiting conditions; b) prolonged acute conditions, often in metabolically unstable patients, requiring complex multi-disciplinary care and IV supplementation over long periods; and c) chronic reversible or irreversible conditions in metabolically stable patients, requiring long-term intravenous supplementation. In adults, SBS appears after massive intestinal resection leaving patients with less than 200 cm of small bowel defines SBS, and a small bowel length of < 100 cm is highly predictive of permanent IF (5-7). While the actual prevalence of SBS in adults is unknown, the estimated prevalence is 1.4 cases per million people in Europe. It varies depending on the region, from 0.4 to approximately 30 cases per million in Poland and Denmark, respectively (8). The prevalence of SBS is lower in regions where there are no major intestinal rehabilitation centers and efficient home PN (HPN) or IV programs, likely because of under-reporting and the inability to adequately treat these patients.

Adaptive changes following resection explain why some patients can be weaned off PN. The degree of intestinal adaptation depends on the underlying pathology for which resection is needed, the unresected anatomic sections of the intestine and the length of the remaining bowel (6,9). Resection of the small bowel results in three different anatomic anastomoses: a) enterostomy; b) jejunocolonic; and c) jejunoleocolonic. In most cases, intestinal adaptation in adults is supposed to occur 1-2 years after

resection, but no objective, clinically practical markers have been identified to determine the time course or extent of adaptation in humans (10). Preserving the colon is essential for reducing the need for PN in SBS patients (6,11). The probability of PN-independence is of 47% five years after surgery and is significantly associated with a remnant small bowel length greater than 75 cm, a large portion of remaining colon and a postoperative citrulline concentration greater than 20  $\mu\text{mol/l}$  (12). The post-absorptive concentration has been shown to correlate with the small bowel length and to be a prognostic factor for HPN dependency (11,12).

## ROLE OF THE COLON IN FLUID AND ELECTROLYTE ABSORPTION

The large intestine or colon measures about 1.5 m in length in adults and consists of four parts: the ascending colon, the transverse colon, the descending colon, and the sigmoid colon. Once the chyme has reached the colon, almost all nutrients and 80-90% of the water have been absorbed in the small intestine. At this point, some electrolytes such as sodium, magnesium and chloride are left as well as indigestible carbohydrates known as dietary fibers. Bacteria, by metabolizing dietary fibers, play a crucial role in the nourishment of the colon and in calorie sparing. Thus, the colon is involved in some clinical disorders such as SBS.

Immediately after extended ileal intestinal resection, gastric hypersecretion associated with hypergastrinemia may be observed (13). Both H<sub>2</sub> antagonists and proton pump inhibitors aim to reduce gastric fluid secretion, and therefore, fluid losses (13-15). Intravenous delivery is usually needed. In patients without colon in continuity or who have a short residual jejunum or duodenum, fluid losses are especially high and a chronic control with antimotility agents such as loperamide or codeine sulphate may be needed. Therefore, in SBS patients, the rapid restoration of intestinal continuity not only helps to control fluid and electrolyte losses but also provides the metabolic benefits of the colon.

## IMPORTANT ROLE OF THE COLON IN SBS PATIENTS

### Metabolic role of the colon

Medium chain triglycerides (MCTs) (C8-C10) contain 8.3 kcal/g, are water-soluble and may be absorbed by the colon. Diets containing MCTs, long chain triglycerides (LCTs) and 50% of MCTs/50% of LCTs have been assessed in a randomized crossover study comparing ten SBS patients with colon in continuity to nine SBS patients without residual colon (16). Patients with intact colon absorbed 96% of C8 and 87% of C10 from the mixed LCT/MCT diet, while energy absorption was significantly increased (500 kcal/day). Patients without residual colon absorbed 63% of C8 and 57% of C10 ( $p = 0.007$  for C8 and  $p = 0.004$  for C10). The LCT/MCT diet did not increase energy absorption in patients who underwent end-jejunostomy or ileostomy.

Some starches and soluble non-starch polysaccharides are not digested by the small intestine. They are fermented later in the colon by colonic bacteria into hydrogen, methane and short chain fatty acids (SCFAs) such as propionate, butyrate and acetate. In the colon, some SCFAs such as butyrate are metabolized and used as a source of fuel by colonic epithelial cells (17-20). It has been estimated that up to 1,000 kcal may be absorbed daily by the adult human colon in the form of SCFAs (21). In SBS animal models, adaptation of the small and large intestines may be improved by adding an elemental diet with pectin, which is also fermented into SCFAs in the colon (22). Supplementing PN with SCFAs or their intracecal administration reduces mucosal atrophy and intestinal immune dysfunction (23-25).

Animal studies have shown that systemic SCFAs may, in addition to their local effects, affect the motility of the stomach and the ileum through neuroendocrine mechanisms, probably by acting on intestinal secretion of proglucagon-derived peptides (GLP-1) and peptide YY (PYY). Systemic and enteral SCFAs exert trophic effects on the jejunal mucosa (17).

In patients with SBS, the colon becomes an important organ for energy salvage (26). About 75 mmol of SCFAs are produced from 10 g of unabsorbed carbohydrates. In SBS patients with intact colon in continuity, the fecal energy loss has been shown to be decreased by 310-740 kcal when they were fed with a diet consisting of 60% carbohydrates (19) and the colonic metabolism of unabsorbed carbohydrates was confirmed by a decrease in fecal carbohydrate losses in patients with colon in continuity. An intact colon may absorb up to 525-1,170 kcal daily from dietary fibers (19,27,28). Colonic energy absorption may also slightly increase during the post-resection adaptation phase, due to an increase in colonic bacterial carbohydrate fermentation (29). This may be due to changes in colonic microbiota in SBS patients as well as an increased concentration or activity of various enzymes such as galactosidase over time during the adaptation phase (29). Since bacterial metabolites such as SCFAs stimulate sodium and water absorption, patients are likely to experience a decrease in fecal fluid and sodium loss (19).

Morphological adaptation occurs in the colon of SBS patients. Both hyperphagia and adaptation of the remaining colon improve patient outcome. A study has assessed the morphology, proliferation status, and expression level of transporters in the epithelium of the remaining colon of SBS adult patients compared to controls (30). The authors have demonstrated the appearance of colonic hyperplasia with an increase in crypt depth compared to a control group. This increase in crypt depth and colonic epithelial cell number could participate in the decrease in PN dependency within two years after restoration of intestinal continuity in SBS patients. Based on clinician experience, the presence of a colon in continuity in SBS patients may help to improve residual intestinal absorption capacity and to decrease PN. Nowadays, the time needed to achieve this physiological process of intestinal adaptation is not yet completely known. After two or three years, the proportion of patients with a decrease in or weaning off PN remains very low. We can assume that the adaptive processes of physiological intestinal adaptation take time after surgery. Oral/enteral feeding

is essential to promote adaptation. Even in cases with very short bowel syndrome, oral feeding should be encouraged, especially when SBS is associated with jejunocolonic anastomosis.

### TRANSPORTER ADAPTATION IN ADULT SBS PATIENTS

Functional absorptive adaptation of the gut has also been reported in SBS patients through the induction of glucose absorption by the intestinal mucosa, net protein intake (31) and calcium absorption (32,33). There are some discrepancies in the literature regarding colonic transporters. An increase in H<sup>+</sup>-coupled oligopeptide (PepT1) transporter and Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE2 and NHE3) mRNA levels has been reported in the colon of SBS patients (34) and in rodents (35). But these data have not been confirmed as part of a SBS human study since similar levels of NHE2, NHE3 and PepT1 have been found compared to controls (30). These differences may be due to various nutritional statuses of patients, the use of different animal models and different times between the surgery and the study. The use of the overexpression of some transporters as an indicator of intestinal adaptation is not yet validated.

### ENDOCRINE FUNCTIONS IN ADULT SBS PATIENTS

In SBS patients, intestinal absorption depends on the intestinal resection site and transit time (36). The accelerated transit time observed in jejunostomy and ileum-resected SBS patients promotes nutrient malabsorption since a precise control of the transit time is required to maintain equilibrium of hydroelectric and energetic balances. Hormones play a key role in gastric emptying and small bowel transit time. The endocrine functional adaptation should be assessed in SBS patients. Elevated fasting plasma levels of GLP1 and GLP2 have been reported in extensive gut resection patients with preserved colon and they further increased after breakfast (37). These two hormones are produced by enteroendocrine L cells located in the ileum and colon. GLP2 increases the absorptive surface via its trophic action on mucosal epithelial cells and GLP1 slows down gastric emptying and intestinal transit (38,39). These effects (increased contact time and surface of nutrients) may potentially improve intestinal absorption (38,40).

### HYPERPHAGIA IN ADULT SBS PATIENTS

Dietary intervention is essential to improve the outcome and reduce PN dependency in SBS patients. Post-surgery, continuous tube feeding (exclusively or in conjunction with oral feeding) significantly increases the net absorption of lipids, proteins and energy compared to oral feeding (2). When oral feeding is possible, oral dietary intake and hyperphagia should be recommended. Specific dietary recommendations should be made depending on

intestinal anatomy. Based on the clinical experience, hyperphagia is reported in 70% of adult SBS patients and is defined as an oral intake > 1.5 times patient resting energy expenditure (REE) (41). Hyperphagia remains an essential mechanism to reduce the need for PN (42).

In hyperphagic patients, enterohormones play a key role. Increased secretions of glucagon-like peptide-1 (GLP-1) and GLP-2 have been reported in preclinical models and in SBS patients with colon in continuity. They orchestrate gastrointestinal functions, including intestinal trophicity, expression of intestinal nutrient transporters and gastro-intestinal motility. Ghrelin, an orexigenic gut hormone, increases food intake through the activation of orexigenic hypothalamic neurons (co-expressing neuropeptide Y and agouti-related peptide). Recently, a study has been conducted to better understand the hormonal mechanisms involved in the development of hyperphagia in an animal model of SBS and in SBS patients (59). An increase in plasma ghrelin concentrations, major changes in hypothalamic neuropeptide levels (increased levels of mRNA coding orexigenic hypothalamic NPY and AgRP) and a greater induction of PYY have been shown in SBS rats with jejunocolonic anastomosis. As hyperphagia leads to an increased amount of nutrients passing through the gastrointestinal tract, this adaptive mechanism may indirectly contribute to the structural and functional adaptations of the mucosa observed in the remaining gut (31,42).

## COLONIC MICROBIOTA COMPOSITION AND METABOLIC FUNCTIONS IN ADULT SBS PATIENTS

The composition of the microbiota of SBS patients highly differs from the common profile observed in healthy humans with intact gastrointestinal tract. The fecal microbiota of healthy humans is mainly composed of a phylogenetic core containing Firmicutes, Bacteroidetes and Actinobacteria. The human gastrointestinal tract is colonized by a dense complex community of microorganisms, mainly composed of anaerobic bacteria in adults, and the dominant groups are *Clostridium leptum*, *Clostridium coccoides* and *Bacteroides-prevotella*. Gut microbiota composition and metabolic functions in SBS patients and healthy controls have been compared (44). The overall bacterial diversity is reduced in SBS patients. The composition of the fecal and colonic mucosa microbiota is unbalanced in SBS: *Lactobacillus* dominates and anaerobic bacteria (*C. leptum*, *C. coccoides* and *Bacteroides*) are under-represented (41,44). *Lactobacillus* overload should be considered massive, since this group contributes little (< 1%) to the complex microbiota population in healthy humans. For this reason, we proposed that the microbiota of SBS patients could be referred to as lactobiota. The essential role of the colon in SBS patients is related to its own absorptive capacity, the metabolic capacity of its specific lactobiota and the reciprocal cross-talk between the lactobiota and the colonic mucosa (43). After resection, the substrates that arrive in the colon are abundant and poorly digested. The fermentation of substrates by gut bacteria helps to maintain gut

ecosystem diversity and to recover energy from nutrients in SBS patients (27). The bioconversion of macromolecules by the gut microbiota into metabolites is carried out by bacteria belonging to various functional groups (sharing similar and complementary activities) resulting in metabolic trophic chains and homeostasis with the colonic epithelium. In SBS, the trophic chains and fermentative end-products are produced by the lactobiota and are different from those produced by a healthy microbiota (44). Resection leads to deep lumen alterations that are favorable to the lactobiota. In SBS patients, due to the short length of the remnant small intestine and colon, the level of oxygen might be too high to promote the growth of anaerobic bacteria. In addition to the potential presence of O<sub>2</sub>, the low fecal pH, rapid transit time, disruption of enterohepatic circulation and large amount of undigested nutrients arriving in the remaining colon may modify the luminal environment. This may create a niche favorable to the proliferation of lactic acid-producing bacteria.

In SBS, the biological signals arising from the microbiota need to be better understood as they are both beneficial (with a high ability to recover energy) and deleterious (with a potential to overproduce D-lactate, as explained in the next section). Fecal microbiota transfer from SBS rats to recipient germ-free (GF) rats triggers colonic changes through crypt deepening (45) and humanized SBS rats (SBS-H) had higher levels of some hormones than rats carrying a conventional microbiota. The microbiota from SBS rats may promote energy recovery since its transfer to GF rats is associated with high plasma levels of leptin. In summary, the microbiota from SBS rats seems to be a reservoir of multiple and complex signals that could modify the postresection adaptation. Several studies have described an increase in fasting plasma GLP-1 levels in SBS patients with jejunocolonic anastomosis or in resected rats (46). In the specific model of SBS-H rats, fecal transplantation resulted in higher plasma GLP-1 levels associated with a higher number of L cells. GLP-1 is a key mediator of the colonic-ileal brake (it inhibits gastro-intestinal motility) in response to nutrients. The increased fasting plasma GLP-1 levels in SBS-H rats may be an adaptive mechanism in response to a high demand of energy that slows down intestinal transit and consequently enables greater nutrient absorption. The higher level of GLP1 in the presence of the microbiota from SBS rats might promote energy recovery.

## FECAL D- AND L-LACTATE AND CLINICAL RISK FOR D-ENCEPHALOPATHY IN ADULT SBS PATIENTS WITH COLON IN CONTINUITY

D-lactic acidosis is very rare in humans. This disease is mainly observed in SBS patients who have a part of or an intact colon in continuity (47). Metabolic acidosis seems to be due to D-lactic acid accumulation but the mechanisms involved in its toxicity are not well understood. D-lactic acid predominantly affects the central nervous system. As D-lactate is converted into pyruvate and the cerebellar level of pyruvate dehydrogenase (the enzyme required to convert pyruvate into acetyl co-A) is limited, the cerebellum may

potentially be damaged in D-lactic acidosis. Indeed, the cerebellar levels of pyruvate dehydrogenase are not sufficient to metabolize all of the additional pyruvate and this, in combination with thiamine deficiency, may result in neurological symptoms (48).

The symptoms of D-lactate acidosis are often transient, making its diagnosis difficult. Clinical suspicion is based on the presence of some symptoms such as slurred speech, ataxia, altered mental status, gait disturbance, weakness, aggressive behavior, explosive speech, feeling drunk, psychosis, or even coma and biological changes: elevated anion gap metabolic acidosis (48). Patients often present with a history of symptoms following consumption of a high-carbohydrate meal. The early identification and correction of metabolic abnormalities improves the neurological symptoms. The therapeutic strategy is based on the decrease of the offending agent (carbohydrates) and treatment to decrease the level of D-lactate-producing bacteria in the colon. Poorly absorbed oral antibiotics (clindamycin, vancomycin, neomycin and kanamycin) are the most effective and may be used. Strategies for preventing future occurrences must be implemented once the acute phase is controlled. The long-term management should focus on avoiding taking the substrates responsible for D-lactate production. A child with SBS and recurrent, debilitating D-lactic acidosis has recently been successfully treated with fecal transplantation (49). Understanding the pathophysiological mechanisms for the effects of D-lactate should help physicians to identify D-lactate acidosis and to improve preventive and therapeutic strategies (48). We have proposed that HCO<sub>3</sub><sup>2-</sup> amount in blood, total fecal lactate and the fecal D/L lactate ratio may become useful tools for identifying SBS patients at risk for D-encephalopathy (Mayeur 2013). However, further investigations are needed to diagnose patients with high risk of D-lactic encephalopathy using the most relevant combination of specific biomarker(s) and to propose a specific microbiota modulation in order to prevent acute episodes.

## A PLACE FOR PHARMACOLOGICAL ADAPTATION

Some recombinant hormones are produced and used as a specific therapy in SBS patients. In controlled clinical trials, the administration of teduglutide, a GLP-2 analog, has reduced by more than 20% the intravenous needs in 63% of patients after a 6-month treatment (50). Teduglutide has been shown to significantly reduce stool wet weight and fecal energy excretion (51). It also significantly increased villus height, crypt depth and the mitotic index in the jejunum of SBS patients with end jejunostomy, whereas crypt depth and the mitotic index did not change in colonic biopsies of SBS patients with an intact colon (51). The purpose of these novel approaches using GLP-2 analogs is to enhance the natural adaptation process, and to reduce intravenous calorie needs. While some patients were weaned off PN, a greater number of patients were able to reduce the frequency of infusions. Patients who received teduglutide showed significant increases in plasma citrulline levels compared to patients receiving a placebo in two phase III studies (52).

While teduglutide is currently marketed and used in some countries with very good results in terms of efficacy in SBS patients, other hormones or combinations will probably be assessed in SBS in the future. In 2013, an open-label, sequential, placebo-controlled study assessing the acute effects of continuous infusions of GLP-1, GLP-2 and their combination (GLP-1 + GLP-2) on intestinal absorption in SBS patients has shown that GLP-1 decreased diarrhea and fecal excretions. Although GLP-1 reduced fecal wet weight, and sodium and potassium excretions, the absolute absorption was not significantly improved.

Recently, liraglutide (a GLP-1 analog) has been given subcutaneously once daily to eight end-jejunostomy patients in the context of an eight-week, open-label pilot study (53). Liraglutide reduced ostomy wet weight output by  $474 \pm 563$  g/d from  $3,249 \pm 1,352$  to  $2,775 \pm 1,187$  g/d ( $p = 0.049$ ).

In the last two decades, a hormonal treatment paradigm focusing on intestinal rehabilitation by promoting intestinal "hyperadaptation" has been proposed in patients with SBS who require PN. But, if we consider all aspects of physiological intestinal adaptation in SBS patients, especially in SBS patients with jejunocolonic anastomosis and a physiological increase of hormone levels such as GLP1, GLP2, PYY in the absence of treatment, conducting further studies assessing the response of new drugs and taking into account the levels of native hormones will be of interest.

## CONCLUSIONS

The morphological and functional alterations described in SBS may contribute to improve nutrient and fluid absorption in the remnant bowel. A better understanding of the cellular, molecular and microbiological mechanisms involved in functional adaptation of the remnant bowel in SBS could help clinicians to optimize the overall nutritional absorption, and thus to reduce or wean patients off PN and to prevent D encephalopathy episodes. It would now be informative to identify molecular and functional links between the three levels of signal integration: control of food intake, remodeling of the intestinal mucosa and balancing of the microbiota. Important issues should be addressed in the future: a) study nutritional peripheral hormones and central hypothalamic neuropeptides that control food intake in SBS patients; b) determine whether mucosal adaptation of the remnant gut is involved in hyperphagia in SBS patients; c) investigate whether the lactobiota of SBS patients contributes to hyperphagia and mucosal hyperplasia; and d) assess the real impact of new drugs such as GLP2 agonist on intestinal adaptation and the specific benefits of these trophic agents in SBS treatment.

## REFERENCES

1. Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. *Clin Nutr* 2015;34(2):171-80.

2. Joly F, Dray X, Corcos O, Barbot L, Kapel N, Messing B. Tube feeding improves intestinal absorption in short bowel syndrome patients. *Gastroenterology* 2009;136(3):824-31.
3. Messing B, Blethen S, Dibaise JK, Matarese LE, Steiger E. Treatment of adult short bowel syndrome with recombinant human growth hormone: a review of clinical studies. *J Clin Gastroenterol* 2006;40(Suppl 2):S75-84.
4. Messing B, Lémann M, Landais P. Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition. *Gastroenterology* 1995;108:1005-15.
5. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. *Gastroenterology* 2003;124(4):1111-34.
6. Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. *Gastroenterology* 1999;117(5):1043-50.
7. Amiot A, Joly F, Alves A, Panis Y, Bouhnik Y, Messing B. Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition. *Am J Gastroenterol* 2009;104(5):1262-70.
8. Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. *Ther Adv Gastroenterol* 2012;5(3):159-71.
9. Goulet O, Joly F. Intestinal microbiota in short bowel syndrome. *Gastroentérologie Clin Biol* 2010;34(Suppl 1):S37-43.
10. Tappenden KA. Intestinal adaptation following resection. *JPEN J Parenter Enteral Nutr* 2014;38(1 Suppl):23S-31S.
11. Amiot A, Messing B, Corcos O, Panis Y, Joly F. Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome. *Clin Nutr* 2013;32(3):368-74.
12. Crenn P, Coudray-Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. *Gastroenterology* 2000;119(6):1496-505.
13. Nightingale JM, Lennard-Jones JE, Walker ER, Farthing MJ. Jejunal efflux in short bowel syndrome. *Lancet* 1990;336(8718):765-8.
14. Nightingale JM, Walker ER, Farthing MJ, Lennard-Jones JE. Effect of omeprazole on intestinal output in the short bowel syndrome. *Aliment Pharmacol Ther* 1991;5(4):405-12.
15. Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. *Gut* 1998;43(6):763-9.
16. Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. *Gut* 1998;43(4):478-83.
17. Koruda MJ, Rolandelli RH, Settle RG, Zimmaro DM, Rombeau JL. Effect of parenteral nutrition supplemented with short-chain fatty acids on adaptation to massive small bowel resection. *Gastroenterology* 1988;95(3):715-20.
18. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. *Gut* 1999;44(6):844-52.
19. Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. *Lancet* 1994;343(8894):373-6.
20. Royall D, Wolever TM, Jeejeebhoy KN. Evidence for colonic conservation of malabsorbed carbohydrate in short bowel syndrome. *Am J Gastroenterol* 1992;87(6):751-6.
21. Tappenden KA, Thomson AB, Wild GE, McBurney MI. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. *JPEN J Parenter Enteral Nutr* 1996;20(5):357-62.
22. Tappenden KA, Thomson AB, Wild GE, McBurney MI. Short-chain fatty acid-supplemented total parenteral nutrition enhances functional adaptation to intestinal resection in rats. *Gastroenterology* 1997;112(3):792-802.
23. Welters CF, Deutz NE, Dejong CH, Soeters PB, Heineman E. Supplementation of enteral nutrition with butyrate leads to increased portal efflux of amino acids in growing pigs with short bowel syndrome. *J Pediatr Surg* 1996;31(4):526-9.
24. Bartholome AL, Albin DM, Baker DH, Holst JJ, Tappenden KA. Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoleal resection in neonatal piglets. *JPEN J Parenter Enteral Nutr* 2004;28(4):210-23.
25. Pratt VC, Tappenden KA, McBurney MI, Field CJ. Short-chain fatty acid-supplemented total parenteral nutrition improves nonspecific immunity after intestinal resection in rats. *JPEN J Parenter Enteral Nutr* 1996;20(4):264-71.
26. Cummings JH, Gibson GR, Macfarlane GT. Quantitative estimates of fermentation in the hind gut of man. *Acta Vet Scand Suppl* 1989;86:76-82.
27. Nordgaard I, Hansen BS, Mortensen PB. Importance of colonic support for energy absorption as small-bowel failure proceeds. *Am J Clin Nutr* 1996;64(2):222-31.
28. Nightingale JM, Lennard-Jones JE, Gertner DJ, Wood SR, Bartram CI. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. *Gut* 1992;33(11):1493-7.
29. Briet F, Flourié B, Achour L, Maurel M, Rambaud JC, Messing B. Bacterial adaptation in patients with short bowel and colon in continuity. *Gastroenterology* 1995;109(5):1446-53.
30. Joly F, Mayeur C, Messing B, Lavergne-Slove A, Cazals-Hatem D, Noordine M-L, et al. Morphological adaptation with preserved proliferation/transporter content in the colon of patients with short bowel syndrome. *Am J Physiol Gastrointest Liver Physiol* 2009;297(1):G116-23.
31. Crenn P, Morin MC, Joly F, Penven S, Thuillier F, Messing B. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. *Gut* 2004;53(9):1279-86.
32. Iqbal CW, Qandeel HG, Zheng Y, Duenes JA, Sarr MG. Mechanisms of ileal adaptation for glucose absorption after proximal-based small bowel resection. *J Gastrointest Surg Off J Soc Surg Aliment Tract* 2008;12(11):1854-65.
33. Hines OJ, Bilchik AJ, Zinner MJ, Skotzko MJ, Moser AJ, McFadden DW, et al. Adaptation of the Na<sup>+</sup>/glucose cotransporter following intestinal resection. *J Surg Res* 1994;57(1):22-7.
34. Ziegler TR, Fernández-Estivariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM, et al. Distribution of the H<sup>+</sup>/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. *Am J Clin Nutr* 2002;75(5):922-30.
35. Musch MW, Bookstein C, Rocha F, Lucioni A, Ren H, Daniel J, et al. Region-specific adaptation of apical Na<sup>+</sup>/H exchangers after extensive proximal small bowel resection. *Am J Physiol Gastrointest Liver Physiol* 2002;283(4):G975-85.
36. Remington M, Malagelada JR, Zinsmeister A, Fleming CR. Abnormalities in gastrointestinal motor activity in patients with short bowels: effect of a synthetic opiate. *Gastroenterology* 1983;85(3):629-36.
37. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. *Gut* 2000;47(3):370-6.
38. Martin GR, Wallace LE, Hartmann B, Holst JJ, Demchyshyn L, Toney K, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. *Am J Physiol Gastrointest Liver Physiol* 2005;288(3):G431-8.
39. Nightingale JM, Kamm MA, Van der Sijp JR, Ghatei MA, Bloom SR, Lennard-Jones JE. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the "colonic brake" to gastric emptying. *Gut* 1996;39(2):267-72.
40. Kunkel D, Basseri B, Low K, Lezcano S, Soffer EE, Conklin JL, et al. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. *Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc* 2011;23(8):739-e328.
41. Mayeur C, Grataudoux J-J, Bridonneau C, Chegiani F, Larroque B, Kapel N, et al. Faecal D/L lactate ratio is a metabolic signature of microbiota imbalance in patients with short bowel syndrome. *PLoS One* 2013;8(11):e54335.
42. Messing B, Pigot F, Rongier M, Morin MC, Ndeindoum U, Rambaud JC. Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. *Gastroenterology* 1991;100(6):1502-8.
43. Mayeur C, Gillard L, Le Beyec J, Bado A, Joly F, Thomas M. Extensive intestinal resection triggers behavioral adaptation, intestinal remodeling and microbiota transition in short bowel syndrome. *Microorganisms* 2016;4(1).
44. Joly F, Mayeur C, Bruneau A, Noordine M-L, Meylheuc T, Langella P, et al. Drastic changes in fecal and mucosa-associated microbiota in adult patients with short bowel syndrome. *Biochimie* 2010;92(7):753-61.
45. Gillard L, Mayeur C, Robert V, Pingenot I, Le Beyec J, Bado A, et al. Microbiota is involved in post-resection adaptation in humans with short bowel syndrome. *Front Physiol* 2017;8:224.
46. Gillard L, Billiauws L, Stan-luga B, Ribeiro-Parenti L, Jarry A-C, Cavin J-B, et al. Enhanced ghrelin levels and hypothalamic orexigenic AgRP and NPY neuropeptide expression in models of jejuno-colonic short bowel syndrome. *Sci Rep* 2016;6:28345.
47. Oh MS, Phelps KR, Traube M, Barbosa-Saldivar JL, Boxhill C, Carroll HJ. D-lactic acidosis in a man with the short-bowel syndrome. *N Engl J Med* 1979;301(5):249-52.
48. Kowligi NG, Chhabra L. D-lactic acidosis: an underrecognized complication of short bowel syndrome. *Gastroenterol Res Pract* 2015;2015:476215.
49. Davidovics ZH, Vance K, Etienne N, Hyams JS. Fecal transplantation successfully treats recurrent D-lactic acidosis in a child with short bowel syndrome. *JPEN J Parenter Enteral Nutr* 2017; 41(5):896-7.

50. Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJD, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. *Gastroenterology* 2012;143(6):1473-81.e3.
51. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. *Gut* 2005;54(9):1224-31.
52. Seidner DL, Joly F, Youssef NN. Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase III randomized trials. *Clin Transl Gastroenterol* 2015;6:e93.
53. Hvistendahl M, Brandt CF, Tribler S, Naimi RM, Hartmann B, Holst JJ, et al. Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: an open-label pilot study. *JPEN J Parenter Enteral Nutr* 2016;148607116672265.